心得安(普萘洛尔)
心得安(普萘洛尔)用途
Propranolol 普萘洛尔是一种非心脏选择性 β 受体阻滞剂 β-blocker。Propranolol 具有膜稳定性质,但不具有内在的拟交感神经活性。Propranolol 用于控制高血压,嗜铬细胞瘤,心肌梗塞,心律失常,心绞痛和肥厚性心肌病。
点击显示
心得安(普萘洛尔)作用
普萘洛尔(心得安)与去甲肾上腺素能神经递质或拟肾上腺素因药物竞争β受体，从而抑制去甲肾上腺素能经神支配器官的β效应。
⒈心血管 对心脏β1受体阻断作用较强，可使心率减慢，心肌收缩力减弱；能降低心肌自律性，延长有效不应期（effective refractory period,ERP），减慢传导，使心输出量减少，心肌耗氧降低，血压稍降低。心得安对心脏抑制作用强度与心脏交感神经的张力大小有关，如运动、病理状态时交感神经的张力增高，心得安对心脏的抑制作用较强，对正常人休息时心脏作用较弱。心得安可反射性引起外周阻力增加，使内脏（肝、肾等）器官血流减少，冠脉流量亦降低。
⒉支气管平滑肌阻断β2受体，可使支气管平滑肌收缩，对支气管哮喘患者可诱发或加重急性发作。
⒊其他 ①内在拟交感神经活动性，有些β受体阻断药物尚有一定程度的兴奋β受体的性能，这种性能是内在拟交感活动性所引起的β受体兴奋效应，往往被β受体阻断效应所掩盖，但可以对抗或减弱β型应用的效果；②膜定作用，有些β受体阻断剂尚有局部麻醉和直接抑制心脏作用（奎尼丁样作用）。这两种作用都是由于稳定细胞膜，使神经纤维或心肌细胞膜对阳离子的通透性降低所致，故统称为膜定作用。
⒈心血管 对心脏β1受体阻断作用较强，可使心率减慢，心肌收缩力减弱；能降低心肌自律性，延长有效不应期（effective refractory period,ERP），减慢传导，使心输出量减少，心肌耗氧降低，血压稍降低。心得安对心脏抑制作用强度与心脏交感神经的张力大小有关，如运动、病理状态时交感神经的张力增高，心得安对心脏的抑制作用较强，对正常人休息时心脏作用较弱。心得安可反射性引起外周阻力增加，使内脏（肝、肾等）器官血流减少，冠脉流量亦降低。
⒉支气管平滑肌阻断β2受体，可使支气管平滑肌收缩，对支气管哮喘患者可诱发或加重急性发作。
⒊其他 ①内在拟交感神经活动性，有些β受体阻断药物尚有一定程度的兴奋β受体的性能，这种性能是内在拟交感活动性所引起的β受体兴奋效应，往往被β受体阻断效应所掩盖，但可以对抗或减弱β型应用的效果；②膜定作用，有些β受体阻断剂尚有局部麻醉和直接抑制心脏作用（奎尼丁样作用）。这两种作用都是由于稳定细胞膜，使神经纤维或心肌细胞膜对阳离子的通透性降低所致，故统称为膜定作用。
点击显示
心得安(普萘洛尔)名称
[ CAS 号 ]:
525-66-6
[ 中文名 ]:
心得安(普萘洛尔)
[ 英文名 ]:
propranolol
[中文别名 ]:
[英文别名 ]:
- Disoprivan
- Propranolol
- Fresofol
- 2,6-diisopropylphenol
- Propofolum
- Disoprofol
- Diprivan
- 2-hydroxy-1,3-diisopropylbenzene
- propofol
- 2,6-i-Pr2-C6H3-OH
心得安(普萘洛尔)生物活性
心得安(普萘洛尔)物理化学性质
[ 密度 ]:
1.093 g/cm3
[ 沸点 ]:
434.9ºC at 760 mmHg
[ 熔点 ]:
163-164ºC
[ 分子式 ]:
C16H21NO2
[ 分子量 ]:
259.34300
[ 闪点 ]:
216.8ºC
[ 精确质量 ]:
259.15700
[ PSA ]:
41.49000
[ LogP ]:
2.96840
[ 外观性状 ]:
白色,无气味的结晶粉末
[ 折射率 ]:
1.5500 (estimate)
[ 储存条件 ]:
室温
心得安(普萘洛尔)毒性和生态
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- UB7500000
- CHEMICAL NAME :
- 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-
- CAS REGISTRY NUMBER :
- 525-66-6
- LAST UPDATED :
- 199709
- DATA ITEMS CITED :
- 29
- MOLECULAR FORMULA :
- C16-H21-N-O2
- MOLECULAR WEIGHT :
- 259.38
- WISWESSER LINE NOTATION :
- L66J BO1YQ1MY1&1
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 708 mg/kg/39W-I
- TOXIC EFFECTS :
- Nutritional and Gross Metabolic - other changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 3200 ug/kg/2D-I
- TOXIC EFFECTS :
- Endocrine - hypoglycemia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 2300 ug/kg/D
- TOXIC EFFECTS :
- Behavioral - hallucinations, distorted perceptions
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 120 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - child
- DOSE/DURATION :
- 800 ug/kg/12H
- TOXIC EFFECTS :
- Cardiac - pulse rate increase, without fall in BP Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - acute pulmonary edema
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - child
- DOSE/DURATION :
- 400 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Cardiac - arrhythmias (including changes in conduction)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 8343 mg/kg/4Y-I
- TOXIC EFFECTS :
- Endocrine - evidence of thyroid hyperfunction
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 71 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 22857 ug/kg/40D-I
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Ear) - change in acuity
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 660 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 23 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 289 mg/kg
- TOXIC EFFECTS :
- Autonomic Nervous System - beta-adrenergic blockage
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 42 mg/kg
- TOXIC EFFECTS :
- Autonomic Nervous System - beta-adrenergic blockage
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 150 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 28100 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 120 mg/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 40 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 26 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 7 gm/kg/35D-C
- TOXIC EFFECTS :
- Liver - other changes Kidney, Ureter, Bladder - other changes Blood - changes in spleen
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1096 mg/kg
- SEX/DURATION :
- female 1-40 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) Reproductive - Effects on Newborn - Apgar score (human only)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Multiple routes
- DOSE :
- 932 mg/kg
- SEX/DURATION :
- female 4-40 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - Apgar score (human only) Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 966 mg/kg
- SEX/DURATION :
- male 6 week(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 650 mg/kg
- SEX/DURATION :
- female 8-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 325 mg/kg
- SEX/DURATION :
- female 8-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - biochemical and metabolic
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 1 mg/kg
- SEX/DURATION :
- female 8 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- DOSE :
- 300 mg/kg
- SEX/DURATION :
- female 10-12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death
MUTATION DATA
- TEST SYSTEM :
- Rodent - mouse
- DOSE/DURATION :
- 74500 ug/kg
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 173,207,1986 *** REVIEWS *** TOXICOLOGY REVIEW FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 6,395,1986 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4181 No. of Facilities: 17 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 1785 (estimated) No. of Female Employees: 355 (estimated)
点击显示
心得安(普萘洛尔)安全信息
[ 海关编码 ]:
2922210000
心得安(普萘洛尔)合成路线
心得安(普萘洛尔)上下游产品
心得安(普萘洛尔)上游产品
心得安(普萘洛尔)下游产品
心得安(普萘洛尔)海关
[ 海关编码 ]: 2922509090
[ 中文概述 ]:
2922509090. 其他氨基醇酚、氨基酸酚及其他含氧基氨基化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件：AB. 最惠国关税:6.5%. 普通关税:30.0%
[ 申报要素 ]: 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装
[ 监管条件 ]: A.入境货物通关单 B.出境货物通关单
[ 检验检疫 ]: R.进口食品卫生监督检验 S.出口食品卫生监督检验
[ Summary ]:
2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
相关化工产品/化学物质：
相关药品：
推荐生产厂家/供应商：
公司名：广东翁江化学试剂有限公司
区域：韶关市翁源县
价格：
￥800.0/250mg
联系人：朱丽丹
产品详情：普萘洛尔
公司名：前衍化学科技（武汉）有限公司
区域：武汉市洪山区
价格：
￥1300.0/100mg
￥2000.0/250mg
￥3600.0/500mg
￥需询单/1g
联系人：田红玲
产品详情：普萘洛尔
查看所有供应商请点击：
心得安(普萘洛尔)相关知识
2018-10-10 14:50:11
心得安(普萘洛尔)是一种β-受体阻滞剂。 β-受体阻滞剂影响心脏和循环（通过动脉和静脉的血流）。心得安(普萘洛尔)用于治疗震颤，心绞痛（胸痛），高血压（高血压），心律紊乱和其他心脏或循环疾病。 它还用于治疗或预防心脏病发作，并降低偏头痛的严重程度和频率。一、服用心得安(普萘洛尔)的副作用：适用于心...
2018-12-16 11:27:35
导读：心得安用于治疗多种原因所致的心律失常，如房性及室性早搏（效果较好）、窦性及室上性心动过速、心房颤动等，但室性心动过速宜慎用。锑剂中毒引起的心律失常，当其他药物无效时，可试用本品。此外，也可用于心绞痛、高血压、嗜铬细胞瘤（手术前准备）等。治心绞痛时，常与硝酸酯类合用。可提高疗效，并互相抵消其不...
相关化合物
【心得安(普萘洛尔)】化源网提供心得安(普萘洛尔)CAS号525-66-6，心得安(普萘洛尔)MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询心得安(普萘洛尔)上化源网，专业又轻松。>>电脑版：心得安(普萘洛尔)
标题：心得安(普萘洛尔)_作用_用途_密度_CAS号【525-66-6】_化源网 地址：https://m.chemsrc.com/mip/cas/525-66-6_684790.html